IP Law 360

OCTOBER 23, 2023

Pharmaceutical company Hoffmann-La Roche Inc. has settled a patent lawsuit alleging that Biogen MA Inc.'s s proposed similar version of Roche's rheumatoid arthritis drug Actemra infringed several patents, according to a joint stipulation of dismissal filed Monday in Massachusetts federal court.

Patent 40

Patent 40

LexBlog IP

FEBRUARY 4, 2022

Last week, Biogen Inc. According to a press release from Samsung Biologics, Biogen initially invested a 15% stake when the joint venture was established in 2012, before exercising its right to purchase up to 50% less one share of Samsung Bioepis in 2018. Billion to Samsung Biologics appeared first on Big Molecule Watch. .”

Business 52

Business Intellectual Property 52

LexBlog IP

SEPTEMBER 23, 2021

and Biogen Inc. As Biogen noted, BYOOVIZ is the first ophthalmology biosimilar approved in the United States. As Biogen noted, BYOOVIZ is the first ophthalmology biosimilar approved in the United States. ” The post Biogen/Samsung Approval of BYOOVIZ™ appeared first on Big Molecule Watch. .”

Licensing 40

Licensing Reporting Marketing Marketing 40

Patently-O

SEPTEMBER 20, 2021

Eligibility : The Supreme Court has shown the most interest in hearing American Axle & Manufacturing, Inc. There are Am.Axle follow-on cases asking the same questions: iLife Technologies, Inc., Nintendo of America, Inc.; VoIP-Pal.com, Inc. Apple, Inc. Patreon, Inc. EMD Serono, Inc. ,

Patent Law 104

Patent Law Law Patent Art 104

Trading Secrets

JANUARY 13, 2022

Biogen, Inc.— upheld the trial court’s granting of summary adjudication in favor of Twentieth Century Fox Film Corporation and Fox 21, Inc. against Netflix Inc. Biogen, Inc. , Netflix, Inc. collectively, “Fox”) on their claim under Business and Professions Code sections 17200, et seq.

Contracts 52

Contracts Business Marketing Marketing 52

LexBlog IP

JANUARY 13, 2022

Biogen, Inc.— — upheld the trial court’s granting of summary adjudication in favor of Twentieth Century Fox Film Corporation and Fox 21, Inc. against Netflix Inc. (“Netflix”) and corresponding injunction in an unpublished but closely followed decision. .” Biogen, Inc. ,

Contracts 52

Contracts Business Marketing Marketing 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

SB11 (Samsung Bioepis/Biogen). As of the March 23, 2020 transition, however, all “biological product” applications previously approved under the FD&C Act were “deemed” approved under the PHS Act, and companies can now seek biosimilars and interchangeables of these biological products. Proposed Biosimilar. Reference Product.

Settlement 52

Settlement Litigation Marketing Marketing 52